Sermorelin
Also: GHRH(1-29)-NH2, GRF(1-29), Geref
4 papers: 4 human studies.
Legal status as understood on this date. Listed, not endorsed. How we list.
Summary
Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment that still triggers the pituitary to release growth hormone. It was developed as a medicine for growth hormone deficiency in children and marketed under the name Geref; there is no current FDA label for it. In Australia it is a prescription-only substance.
What it targets
Sermorelin prompts the pituitary's own growth hormone release rather than supplying growth hormone directly. In 30 healthy men, intravenous administration produced measurable growth hormone release even at the smallest amount tested, with the peptide clearing quickly while growth hormone stayed raised for around three hours; absorbed through the nose, only 3 to 5 percent reached the bloodstream. In a randomised six-month study of 43 children with growth hormone deficiency of hypothalamic origin, higher-dose sermorelin and growth hormone itself produced comparable height velocity, though only the growth hormone group gained height relative to bone age. A six-month nasal pilot in eight children found the response weakened over time, three children developed antibodies, and height velocity did not increase; the authors concluded the nasal form as tested was unsuitable. In seven children with idiopathic short stature and normal growth hormone, some grew well over two years.
Clinical Research
Suppliers stocking Sermorelin
22 of the 49 listed suppliers. Each row opens its full listing.